Reduction of Urinary Levels of Pyridinoline and Deoxypyridinoline and Serum Levels of Soluble Receptor Activator of NF-kappaB Ligand by Etanercept in Patients with Rheumatoid Arthritis

Overview

Journal Clin Rheumatol

Publisher Springer

Specialty Rheumatology

Date 2008 Mar 14

PMID 18338203

Citations 15

Authors

Kageyama Yasunori

Takahashi Masaaki

Nagafusa Tetsuyuki

Kobayashi Hayato

Nagano Akira

Affiliations

Soon will be listed here.

Abstract

The effects of soluble TNF-alpha receptor, etanercept, on bone metabolism were investigated in patients with rheumatoid arthritis (RA). Thirty RA patients were administered etanercept once or twice a week for more than 6 months. We evaluated clinical and laboratory parameters and measured urinary excretion levels of pyridinoline (PYD), deoxypyridinoline (DPD), cross-linked N-telopeptides of type I collagen (NTX), and serum levels of bone alkaline phosphatase (BAP), osteoprotegerin (OPG), and soluble receptor activator of NFkappaB ligand (sRANKL) at the baseline and at 3 and 6 months after initial treatment with etanercept. Etanercept treatment resulted in an improvement of symptoms due to RA and in a reduction of urinary excretion levels of PYD and DPD as well as serum sRANKL levels, with a significant difference at 6 months, and an increase of serum BAP levels at 3 and 6 months after the initial treatment with etanercept. Urinary NTX and serum OPG levels did not show a significant change at 3 and 6 months after the initial treatment, but serum OPG levels did show a reverse correlation with serum CRP levels, suggesting that the regulation of inflammation in RA may result in an induction of OPG production. Etanercept may have the ability to reduce the levels of bone resorption markers and to increase the levels of a bone formation marker while reducing sRANKL formation in RA patients.

Citing Articles

Positive Effects of Biologics on Osteoporosis in Rheumatoid Arthritis.

Kim Y, Kim G J Rheum Dis. 2023; 30(1):3-17.

PMID: 37476528 PMC: 10351356. DOI: 10.4078/jrd.22.0046.

Bone Turnover Markers: Basic Biology to Clinical Applications.

Schini M, Vilaca T, Gossiel F, Salam S, Eastell R Endocr Rev. 2022; 44(3):417-473.

PMID: 36510335 PMC: 10166271. DOI: 10.1210/endrev/bnac031.

Different Effects of Biologics on Systemic Bone Loss Protection in Rheumatoid Arthritis: An Interim Analysis of a Three-Year Longitudinal Cohort Study.

Chen M, Yu S, Chen J, Chen W, Liou T, Chou C Front Immunol. 2022; 12:783030.

PMID: 34987510 PMC: 8720866. DOI: 10.3389/fimmu.2021.783030.

Bone Metabolism and RANKL/OPG Ratio in Rheumatoid Arthritis Women Treated with TNF-α Inhibitors.

Jura-Poltorak A, Szeremeta A, Olczyk K, Zon-Giebel A, Komosinska-Vassev K J Clin Med. 2021; 10(13).

PMID: 34209821 PMC: 8267676. DOI: 10.3390/jcm10132905.

The impact of long-term biologics/target therapy on bone mineral density in rheumatoid arthritis: a propensity score-matched analysis.

Chen J, Hsu C, Yu S, Ko C, Chiu W, Lai H Rheumatology (Oxford). 2020; 59(9):2471-2480.

PMID: 31984422 PMC: 7449814. DOI: 10.1093/rheumatology/kez655.

References

Gorai I, Taguchi Y, Chaki O, Nakayama M, MINAGUCHI H . Specific changes of urinary excretion of cross-linked N-telopeptides of type I collagen in pre- and postmenopausal women: correlation with other markers of bone turnover. Calcif Tissue Int. 1997; 60(4):317-22. DOI: 10.1007/s002239900235. View

Aubin J, Bonnelye E . Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int. 2001; 11(11):905-13. DOI: 10.1007/s001980070028. View

Sambrook P . The skeleton in rheumatoid arthritis: common mechanisms for bone erosion and osteoporosis?. J Rheumatol. 2000; 27(11):2541-2. View

Geusens P, Landewe R, Garnero P, Chen D, Dunstan C, Lems W . The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum. 2006; 54(6):1772-7. DOI: 10.1002/art.21896. View

Martin J, Munro R, Campbell M, Reid D . Effects of disease and corticosteroids on appendicular bone mass in postmenopausal women with rheumatoid arthritis: comparison with axial measurements. Br J Rheumatol. 1997; 36(1):43-9. DOI: 10.1093/rheumatology/36.1.43. View

Butler R, Davie M, Worsfold M, Sharp C . Bone mineral content in patients with rheumatoid arthritis: relationship to low-dose steroid therapy. Br J Rheumatol. 1991; 30(2):86-90. DOI: 10.1093/rheumatology/30.2.86. View

Seriolo B, Paolino S, Sulli A, Cutolo M . [Are there any positive effects of TNF-alpha blockers on bone metabolism?]. Reumatismo. 2006; 58(3):199-205. DOI: 10.4081/reumatismo.2006.199. View

Takahashi M, Hoshino H, Kushida K, Inoue T . Direct measurement of crosslinks, pyridinoline, deoxypyridinoline, and pentosidine, in the hydrolysate of tissues using high-performance liquid chromatography. Anal Biochem. 1995; 232(2):158-62. DOI: 10.1006/abio.1995.0002. View

Gravallese E . Bone destruction in arthritis. Ann Rheum Dis. 2002; 61 Suppl 2:ii84-6. PMC: 1766721. DOI: 10.1136/ard.61.suppl_2.ii84. View

10.

Black D, Marabani M, Sturrock R, Robins S . Urinary excretion of the hydroxypyridinium cross links of collagen in patients with rheumatoid arthritis. Ann Rheum Dis. 1989; 48(8):641-4. PMC: 1003839. DOI: 10.1136/ard.48.8.641. View

11.

Kalla A, Meyers O, Laubscher R . Prevalence of metacarpal osteopenia in young rheumatoid arthritis patients. Clin Rheumatol. 1995; 14(6):617-25. DOI: 10.1007/BF02207926. View

12.

Kageyama Y, Takahashi M, Torikai E, Suzuki M, Ichikawa T, Nagafusa T . Treatment with anti-TNF-alpha antibody infliximab reduces serum IL-15 levels in patients with rheumatoid arthritis. Clin Rheumatol. 2006; 26(4):505-9. DOI: 10.1007/s10067-006-0312-4. View

13.

Kwon B, Wang S, Udagawa N, Haridas V, Lee Z, Kim K . TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption. FASEB J. 1998; 12(10):845-54. DOI: 10.1096/fasebj.12.10.845. View

14.

Haugeberg G, Uhlig T, Falch J, Halse J, Kvien T . Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum. 2000; 43(3):522-30. DOI: 10.1002/1529-0131(200003)43:3<522::AID-ANR7>3.0.CO;2-Y. View

15.

Kong Y, Yoshida H, Sarosi I, Tan H, Timms E, Capparelli C . OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999; 397(6717):315-23. DOI: 10.1038/16852. View

16.

Ravn P, Clemmesen B, Christiansen C . Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone. 1999; 24(3):237-44. DOI: 10.1016/s8756-3282(98)00183-5. View

17.

Simonet W, Lacey D, Dunstan C, Kelley M, Chang M, Luthy R . Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997; 89(2):309-19. DOI: 10.1016/s0092-8674(00)80209-3. View

18.

Lane N, Pressman A, Star V, Cummings S, Nevitt M . Rheumatoid arthritis and bone mineral density in elderly women. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res. 1995; 10(2):257-63. DOI: 10.1002/jbmr.5650100212. View

19.

Iwamoto J, Takeda T, Ichimura S . Urinary cross-linked N-telopeptides of type I collagen levels in patients with rheumatoid arthritis. Calcif Tissue Int. 2003; 72(4):491-7. DOI: 10.1007/s00223-002-1024-7. View

20.

Celiker R, Gokce-Kutsal Y, Cindas A, Ariyurek M, Renda N, Koray Z . Osteoporosis in rheumatoid arthritis: effect of disease activity. Clin Rheumatol. 1995; 14(4):429-33. DOI: 10.1007/BF02207677. View